Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new drug, BMF-219, to see if it is safe and effective in treating adults with acute leukemia, diffuse large B-cell lymphoma, and multiple myeloma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My lymphoma has worsened or remained despite treatment.I have plasma cell leukemia, myeloma with amyloidosis, or systemic light chain amyloidosis.I can care for myself and doctors expect me to live more than 3 months.My organs are working well.My multiple myeloma can be measured.My condition is primary mediastinal B-cell lymphoma or DLBCL not from indolent NHL.I have APL or CML in blast crisis.My leukemia is actively affecting my brain or spinal cord.You have tested positive for HIV, hepatitis C, or hepatitis B surface antigen.I am 18 years old or older.My acute leukemia has returned or is not responding to treatment.My white blood cell count is over 50,000 and cannot be controlled with treatment.I do not have any ongoing serious infections.My cancer diagnosis was confirmed through lab tests.My cancer affects my brain or its coverings.I have active brain or spinal cord multiple myeloma.My leukemia has spread to my brain (CNS).I have previously received menin inhibitor therapy.I am using or willing to use birth control during and 90 days after the trial.I have or might have had Richter's transformation.I have a condition that makes me prone to serious infections.I have CLL/SLL and meet the criteria for needing treatment.My cancer did not respond or got worse after my last cancer treatment.
- Group 1: Dose Escalation Phase
- Group 2: Dose Expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How detrimental could BMF-219 be to human health?
"BMF-219 was assigned a safety score of 1 due to the limited data available at this early stage in its development. Phase 1 trials only provide preliminary evidence for both effectiveness and safeguard."
How many participants are being recruited for this research endeavor?
"Affirmative. The information on clinicaltrials.gov reveals that the study is presently recruiting participants and has been since January 24th 2022. Last edited on October 24th 2022, this medical trial seeks to enrol 120 individuals between 12 locations."
How widespread is the implementation of this research in Canada?
"The current clinical trial has a total of 12 sites, including UC Davis Comprehensive Cancer Center (Sacramento), Blood & Marrow Transplant Group of GA (Northside Hospital) in Atlanta and Mount Sinai Medical Centre in Miami Beach. Additionally, there are 9 other participating locations."
Are there any available slots left to participate in this experiment?
"The data on clinicaltrials.gov depicts an ongoing recruitment for this trial, which was initially made available to the public on January 24th 2022 and recently updated in October of that same year."
Share this study with friends
Copy Link
Messenger